A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
What is rheumatoid arthritis?
In RA, the immune system mistakes the lining of your joints for a threat and attacks it. The result is inflammation that hurts, swells, and over time can damage cartilage and bone. It usually shows up symmetrically, both hands or both knees, and morning stiffness that lasts more than an hour is a classic sign. RA typically starts between 40 and 60, but it can begin at any age. Worldwide about 18 million people have it.
RA is a whole body disease, not just a joint disease. Roughly 1 in 10 people with RA develop interstitial lung disease, scarring of the lung tissue, according to a 2026 review of 74 studies. RA also raises the risk of heart disease, and fatigue and low mood are common enough that some studies now target them directly. The good news: treatment works far better than it did a generation ago. Methotrexate is still the usual first medicine, and when it is not enough, doctors can choose from more than a dozen biologic and targeted oral drugs. Yet about 30 to 40 percent of people with severe RA still do not get adequate control even after several of them, which is exactly the group new research is built around.
Types of rheumatoid arthritis clinical trials
RA research is broader than new pills and injections. Studies on our platform right now include:
Treatment trials. New medicines or new ways to use existing ones, usually in people whose current treatment is not working well enough. Some test a completely new mechanism, others compare two approved drugs head to head to learn which works better for whom.
Cell therapy and immune reset studies. A small but fast moving area. Instead of suppressing the immune system for life, these therapies try to reset it. The first published RA trial of this kind reported results in August 2026.
Lung and heart studies. Because RA affects organs beyond the joints, some studies screen people with RA for early lung disease or track heart risk over time.
Exercise, diet, and lifestyle studies. These test how much exercise helps, whether probiotics change disease activity, or how to support people dealing with RA and mood problems together.
Observational studies. No treatment is given. Researchers follow people over time or collect blood samples to understand what drives the disease, which is how tomorrow's targets get found.
Who can participate in RA clinical trials?
Most RA studies look at three things. Your disease activity, measured with scores your rheumatologist uses like DAS28 or CDAI, which combine tender and swollen joint counts with blood markers of inflammation. Your antibody status, because many trials enroll only people who test positive for anti-CCP or rheumatoid factor. And your treatment history: some studies want people who have never taken a biologic, others specifically want people who have tried several without success. A few studies also welcome people with joint symptoms who do not yet have full RA, since preventing the disease is a new research goal. Eligibility always varies by study.
How RA severity is measured, and why it matters for trials
RA has no stage 1 to 4 system. Doctors measure disease activity instead, usually with the DAS28 or CDAI score, and sort it into remission, low, moderate, or high. Treatment guidelines follow a treat to target approach: adjust medicines until you reach remission or low disease activity, then keep it there. Most treatment trials enroll people in the moderate or high range, so knowing your last score tells you which studies fit. Being in remission does not close doors either: tapering studies and observational studies often want exactly those participants.
Do RA trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to Enroll in a Clinical Trial for Rheumatoid Arthritis
Enrolling in an RA clinical trial through our platform is a straightforward and user-friendly undertaking. The process involves five key steps:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to your requirements.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar.
- Explore Study Details: For in-depth information about each study, simply click the "Learn More" button.
- Complete the Health Profile: After clicking on the "Get started" button you will be taken to our efficient 5-step application process.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you.